BOSTON, June 9, 2025 - Elevation Oncology, Inc. (Nasdaq: ELEV) announced that it has entered into a definitive merger agreement with Concentra Biosciences, LLC, under which Concentra will acquire Elevation Oncology for $0.36 in cash per share, along with a contingent value right. This right includes potential additional payments based on net cash and proceeds from EO-1022 disposition within specified conditions. The merger is set to progress with a tender offer commencing by June 23, 2025, and is expected to close in July 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.